06:54 AM EDT, 06/25/2025 (MT Newswires) -- Novo Nordisk ( NVO ) is under investigation by Spain's ministry of health over its website communications on its weight-loss drug, it emerged Wednesday.

The Spanish government body said the communications on the website "could be considered as covert advertising of prescription drugs, which is prohibited by current legislation," according to a translation of a June 19 statement.

The ministry said it has sent Novo Nordisk ( NVO ) a request for clarification.

"Although no pharmacological treatment is explicitly mentioned, the ministry considers that all the content could constitute a form of indirect advertising of medicines subject to medical prescription," the ministry said.

Novo Nordisk ( NVO ) did not immediately reply to MT Newswires' request for comment.

Shares of the company were down more than 2% in recent premarket activity on Wednesday.